ANTITETANUS TOXOID ANTIBODY TITER OF CHRONIC HEMODIALYSIS PATIENTS IN IRAN

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

SAGHEB M.M.; SAJADI SH.; SAJADI G.M.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Iranian Journal of Immunology Year:2008 | Volume:5 | Issue:1 Page(s): 45-50

Download Full-Text

View:

392

Download:

280

Cites:

Information Journal Paper

Title

ANTITETANUS TOXOID ANTIBODY TITER OF CHRONIC HEMODIALYSIS PATIENTS IN IRAN

Author(s)

SAGHEB M.M. | SAJADI SH. | SAJADI G.M. | Issue Writer Certificate

Keywords

ANTITETANUS IGG

HEMODIALYSIS

CHRONIC RENAL FAILURE

Abstract

Background: Patients with end stage renal disease have higher incidence of infection diseases that is thought to be related to impaired immune system.Objective: To determine the ANTITETANUS IGG antibody level in Iranian HEMODIALYSIS patients with end stage renal disease and to find its association with sex, age, blood hemoglobin, serum albumin, duration of dialysis, time of dialysis per week, dialysis adequacy, erythropoietin, or iron supplementation, body mass index (BM!) and underlying renal disorder.Methods: We conducted a cross sectional study on a total of 108 Iranian HEMODIALYSIS patients with end stage renal disorder, and 36 healthy individuals in the control group matched with the patient group. The patients and controls did not receive any antitetanus vaccine or immunoglobulins a year prior to the investigation. The serum ANTITETANUS IGG antibody levels were measured by an ELISA method.Results: We found 74.3% of patients to have unprotected ANTITETANUS IGG antibody level compared with 52.8% of the control group. Except HEMODIALYSIS duration, none of the contributing factors seemed to affect immunity.Conclusion: We conclude that in our study; there is a significant difference in the ANTITETANUS IGG antibody level between HEMODIALYSISpatients and the control group and also in the chronic HEMODIALYSISpatients.

Cites

No record.

References

No record.

Cite

APA: Copy

SAGHEB, M.M., SAJADI, SH., & SAJADI, G.M.. (2008). ANTITETANUS TOXOID ANTIBODY TITER OF CHRONIC HEMODIALYSIS PATIENTS IN IRAN. IRANIAN JOURNAL OF IMMUNOLOGY (IJI), 5(1), 45-50. SID. https://sid.ir/paper/296806/en

Vancouver: Copy

SAGHEB M.M., SAJADI SH., SAJADI G.M.. ANTITETANUS TOXOID ANTIBODY TITER OF CHRONIC HEMODIALYSIS PATIENTS IN IRAN. IRANIAN JOURNAL OF IMMUNOLOGY (IJI)[Internet]. 2008;5(1):45-50. Available from: https://sid.ir/paper/296806/en

IEEE: Copy

M.M. SAGHEB, SH. SAJADI, and G.M. SAJADI, “ANTITETANUS TOXOID ANTIBODY TITER OF CHRONIC HEMODIALYSIS PATIENTS IN IRAN,” IRANIAN JOURNAL OF IMMUNOLOGY (IJI), vol. 5, no. 1, pp. 45–50, 2008, [Online]. Available: https://sid.ir/paper/296806/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops